FDA Approves First mRNA-Based Flu Vaccine, Highlighting Growing Patent Value in mRNA Platforms
Key Takeaway: The FDA’s approval of mFLUSIVA may indicate increased commercial and strategic value of mRNA vaccine patents. On August 5, 2026, Moderna announced that the U.S. Food and Drug...
Avoiding Greenwashing Claims: Litigation Risks and Regulatory Guidance
Key Takeaway: Energy companies that market their technologies as environmentally friendly should ensure the claims are accurate and consistent with regulatory guidance. Innovation in the energy industry is often driven...
The Biggest Patent Cases of 2026 So Far: The Federal Circuit Tackles Patentability
Following their discussion on the Supreme Court’s consequential decision in Hikma v. Amarin, Knobbe Martens partners Jeremiah Helm and Carol Pitzel Cruz continue their exploration of the biggest patent cases...